SCHEMBL17847256

SCHEMBL17847256

Ic1nc2c(NCc3ccccc3)ncnc2n1C1CCCCO1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.68
▸ RAB9A P51151 2/20 0.68
▸ SMN1; SMN2 Q16637 2/20 0.68
▸ TDP1 Q9NUW8 2/20 0.47
▸ TMIGD3 P0DMS9 3/20 0.47
▸ ADORA2A P29274 3/20 0.47
▸ ADORA1 P30542 3/20 0.47
▸ ADORA2B P29275 2/20 0.47
▸ CDK1 P06493 4/20 0.46
▸ CTSL P07711 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ PDE4A P27815 2/20 0.43
▸ PDE4B Q07343 2/20 0.43
▸ PDE4C Q08493 2/20 0.43
▸ PDE4D Q08499 2/20 0.43
▸ CCNB2 O95067 1/20 0.43
▸ CCNB1 P14635 1/20 0.43
▸ CDK2 P24941 1/20 0.43
▸ CCNB3 Q8WWL7 1/20 0.43
▸ CYP1A2 P05177 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17847268 0.89 NPC1 (0.67) NPC1RAB9ASMN1; SMN2TDP1TMIGD3
SCHEMBL17847280 0.87 NPC1 (0.65) NPC1RAB9ASMN1; SMN2TDP1TMIGD3
SCHEMBL17847254 0.85 SMN1; SMN2 (0.50) NPC1RAB9ASMN1; SMN2CDK1ALDH1A1
SCHEMBL29366631 0.81 NPC1 (1.00) NPC1RAB9ASMN1; SMN2TDP1CDK1
SCHEMBL218275 0.81 NPC1 (1.00) NPC1RAB9ASMN1; SMN2TDP1CDK1
SCHEMBL17847262 0.78 SMN1; SMN2 (0.54) NPC1RAB9ASMN1; SMN2TDP1TMIGD3
SCHEMBL17289798 0.77 CYP1A2 (0.45) NPC1RAB9ASMN1; SMN2ALDH1A1CYP1A2
SCHEMBL17847259 0.75 SMN1; SMN2 (0.49) NPC1RAB9ASMN1; SMN2TMIGD3ADORA2A
SCHEMBL17847258 0.75 SMN1; SMN2 (0.49) NPC1RAB9ASMN1; SMN2CDK1ALDH1A1
SCHEMBL17847284 0.75 SMN1; SMN2 (0.49) NPC1RAB9ASMN1; SMN2CDK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10093675-B2 6,8-disubstituted-9-(heterocyclyl)purines, compositions containing these derivatives and their use in cosmetic and medicinal applications USTAV EXPERIMENTALNI BOTANIKY AV CR, V.V.I. (CZ) 2018-10-09 — — US disclosed
US-20170362236-A1 6,8-DISUBSTITUTED-9-(HETEROCYCLYL)PURINES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN COSMETIC AND MEDICINAL APPLICATIONS USTAV EXPERIMENTALNI BOTANIKY AV CR, V.V.I. (CZ) 2017-12-21 — — US disclosed
EP-3233861-A1 6,8-DISUBSTITUTED-9-(HETEROCYCLYL)PURINES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN COSMETIC AND MEDICINAL APPLICATIONS Ustav Experimentalni Botaniky Av CR, V.V.I. (CZ) 2017-10-25 — — EP disclosed
WO-2016095880-A1 6,8-DISUBSTITUTED-9-(HETEROCYCLYL)PURINES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN COSMETIC AND MEDICINAL APPLICATIONS USTAV EXPERIMENTALNI BOTANIKY AV CR, V.V.I. (CZ) 2016-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362236-A1 6,8-DISUBSTITUTED-9-(HETEROCYCLYL)PURINES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN COSMETIC AND MEDICINAL APPLICATIONS PNP, UNG, NUDT1 NPC1 3580/4885RAB9A 1999/4885SMN1; SMN2 3293/4885
US-10093675-B2 6,8-disubstituted-9-(heterocyclyl)purines, compositions containing these derivatives and their use in cosmetic and medicinal applications PNP, UNG, NUDT1 NPC1 3580/4885RAB9A 1999/4885SMN1; SMN2 3293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback